{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T05:02:12Z","timestamp":1784869332735,"version":"3.55.0"},"reference-count":32,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T00:00:00Z","timestamp":1784851200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Nutr."],"abstract":"\n Background<\/jats:title>\n Sarcopenia, characterized by loss of skeletal muscle, is associated with unfavorable clinical outcomes in patients with cancer. The creatinine-to-cystatin C ratio (CCR) has emerged as a readily available marker related to muscle reserve. This meta-analysis aimed to examine the prognostic utility of baseline CCR levels in patients with digestive tract cancers.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n We searched PubMed, Embase, Web of Science, and the Cochrane Library from database inception through 22 October 2025. Original cohort studies that enrolled adults with histologically proven digestive tract cancers, reported pretreatment CCR with overall survival hazard ratios, and classified patients using a specific CCR cut-off were included. Risk of bias was evaluated with the Newcastle-Ottawa Scale and the Quality in Prognostic Studies tool. Pooled hazard ratios for overall survival were synthesized. Patient-level survival data were reconstructed from published Kaplan-Meier curves. No original patient-level datasets were obtained from study investigators. Trial sequential analysis (TSA) was performed as an exploratory robustness assessment.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Nine independent cohorts comprising 3,073 patients were included. Lower CCR was significantly associated with shorter OS (HR = 1.71; 95% CI: 1.45\u20132.02;\n p<\/jats:italic>\n &lt; 0.001). Stratified analyses showed consistent prognostic associations in esophageal cancer (HR = 2.21; 95% CI: 1.35\u20133.61;\n p<\/jats:italic>\n = 0.002), biliary tract cancer (HR = 2.62; 95% CI: 1.31\u20135.23;\n p<\/jats:italic>\n = 0.006), and gastrointestinal cancers (HR = 1.65; 95% CI: 1.34\u20132.05;\n p<\/jats:italic>\n &lt; 0.001). Reconstructed IPD analysis also showed shorter OS in the low-CCR group (HR = 1.48; 95% CI: 1.32\u20131.67;\n p<\/jats:italic>\n &lt; 0.001). Exploratory trial sequential analysis was consistent with the pooled OS association under prespecified assumptions.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n Pretreatment CCR was associated with overall survival in patients with digestive tract cancers. However, further prospective studies are needed to confirm these findings.<\/jats:p>\n <\/jats:sec>\n \n Systematic review registration<\/jats:title>\n \n https:\/\/www.crd.york.ac.uk\/prospero\/<\/jats:ext-link>\n , identifier CRD420261290556.\n <\/jats:p>\n <\/jats:sec>","DOI":"10.3389\/fnut.2026.1834663","type":"journal-article","created":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T04:24:51Z","timestamp":1784867091000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Pretreatment creatinine-to-cystatin c ratio as a prognostic marker in digestive tract cancers: a meta-analysis with reconstructed individual patient data and trial sequential analysis"],"prefix":"10.3389","volume":"13","author":[{"given":"Yongping","family":"Hao","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, The First Affiliated Hospital of China Medical University","place":["Shenyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenhui","family":"Li","sequence":"additional","affiliation":[{"name":"Laboratory of Gastrointestinal Onco-Pathology, Cancer Institute and General Surgery Institute, The First Affiliated Hospital of China Medical University","place":["Shenyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangwei","family":"Tian","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, The First Affiliated Hospital of China Medical University","place":["Shenyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, The First Affiliated Hospital of China Medical University","place":["Shenyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"e45705","DOI":"10.1097\/MD.0000000000045705","article-title":"Association between depressive symptoms and sarcopenia in Chinese elderly: a cross-sectional analysis of Chinese longitudinal healthy longevity survey.","volume":"104","author":"Huo","year":"2025","journal-title":"Medicine"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1007\/s00520-025-10089-5","article-title":"Effect of preoperative cancer cachexia on postoperative sarcopenia in patients with non-small cell lung cancer.","volume":"33","author":"Shirado","year":"2025","journal-title":"Support Care Cancer"},{"key":"B3","doi-asserted-by":"publisher","first-page":"112953","DOI":"10.1016\/j.exger.2025.112953","article-title":"Causal relationships between sarcopenia, frailty, and health outcomes: a systematic review of mendelian randomization studies.","volume":"212","author":"Kilait\u0117","year":"2025","journal-title":"Exp Gerontol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"423","DOI":"10.3892\/ol.2025.15169","article-title":"Research progress on evaluation methods for skeletal muscle mass assessment in sarcopenia.","volume":"30","author":"Wu","year":"2025","journal-title":"Oncol Lett"},{"key":"B5","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1186\/s12967-025-06575-3","article-title":"Biomarkers for sarcopenia, muscle mass, muscle strength, and physical performance: an umbrella review.","volume":"23","author":"Liu","year":"2025","journal-title":"J Transl Med"},{"key":"B6","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1097\/MNH.0000000000001022","article-title":"Serum creatinine and serum cystatin C as an index of muscle mass in adults.","volume":"33","author":"Liu","year":"2024","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1655488","DOI":"10.3389\/fnut.2025.1655488","article-title":"Creatinine-to-cystatin C ratio as muscle assessment tool and predictive value for mortality and sarcopenia in patients with chronic kidney disease: a meta-analysis.","volume":"12","author":"Zheng","year":"2025","journal-title":"Front Nutr"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1058464","DOI":"10.3389\/fmed.2022.1058464","article-title":"Serum creatinine\/cystatin C ratio as a muscle mass evaluating tool and prognostic indicator for hospitalized patients: a meta-analysis.","volume":"9","author":"Zheng","year":"2023","journal-title":"Front Med"},{"key":"B9","doi-asserted-by":"publisher","first-page":"2064","DOI":"10.1002\/jcsm.13006","article-title":"Creatinine-cystatin C ratio and mortality in cancer patients: a retrospective cohort study.","volume":"13","author":"Jung","year":"2022","journal-title":"JCSM."},{"key":"B10","doi-asserted-by":"publisher","first-page":"963265","DOI":"10.3389\/fnut.2022.963265","article-title":"Serum creatinine\/cystatin C ratio is a systemic marker of sarcopenia in patients with gastrointestinal stromal tumours.","volume":"9","author":"Ding","year":"2022","journal-title":"Front Nutr"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1645874","DOI":"10.3389\/fimmu.2025.1645874","article-title":"Serum creatinine to cystatin C ratio is a prognostic indicator in esophageal squamous cell carcinoma receiving neoadjuvant immunochemotherapy.","volume":"16","author":"Feng","year":"2025","journal-title":"Front Immunol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews.","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"B13","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/1471-2288-7-10","article-title":"Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews.","volume":"7","author":"Shea","year":"2007","journal-title":"BMC Med Res Methodol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"280","DOI":"10.7326\/0003-4819-158-4-201302190-00009","article-title":"Assessing bias in studies of prognostic factors.","volume":"158","author":"Hayden","year":"2013","journal-title":"Ann Intern Med"},{"key":"B15","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses.","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.2307\/2533446","article-title":"Operating characteristics of a rank correlation test for publication bias.","volume":"50","author":"Begg","year":"1994","journal-title":"Biometrics."},{"key":"B17","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test.","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"B18","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1111\/j.0006-341x.2000.00455.x","article-title":"Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis.","volume":"56","author":"Duval","year":"2000","journal-title":"Biometrics"},{"key":"B19","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1016\/j.jclinepi.2007.10.007","article-title":"Trial sequential analysis reveals insufficient information size and potentially false positive results in many meta-analyses.","volume":"61","author":"Brok","year":"2008","journal-title":"J Clin Epidemiol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1186\/s12874-025-02716-w","article-title":"Trial Sequential Analysis for dichotomous outcomes - a practical guide for systematic review protocols.","volume":"25","author":"Juul","year":"2025","journal-title":"BMC Med Res Methodol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1016\/S1470-2045(25)00429-2","article-title":"Long-term overall survival with dual CTLA-4 and PD-L1 or PD-1 blockade and biomarker-based subgroup analyses in patients with advanced non-small-cell lung cancer: a systematic review and reconstructed individual patient data meta-analysis.","volume":"26","author":"Di Federico","year":"2025","journal-title":"Lancet Oncol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1155520","DOI":"10.3389\/fonc.2023.1155520","article-title":"Serum creatinine\/cystatin C ratio as a prognostic indicator for patients with colorectal cancer.","volume":"13","author":"Gao","year":"2023","journal-title":"Front Oncol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s12876-022-02093-4","article-title":"Serum creatinine\/cystatin C ratio as a surrogate marker for sarcopenia in patients with gastric cancer.","volume":"22","author":"Sun","year":"2022","journal-title":"BMC Gastroenterol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1364728","DOI":"10.3389\/fimmu.2024.1364728","article-title":"Creatinine-to-cystatin C ratio and body composition predict response to PD-1 inhibitors-based combination treatment in metastatic gastric cancer.","volume":"15","author":"Ji","year":"2024","journal-title":"Front Immunol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1186\/s12967-023-04628-z","article-title":"Sarcopenia and myosteatosis diagnostic tool for gastrointestinal cancer: creatinine to cystatin C ratio as evaluation marker.","volume":"21","author":"Liu","year":"2023","journal-title":"J Transl Med"},{"key":"B26","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1186\/s12877-022-02925-8","article-title":"Serum creatinine\/cystatin C ratio as a screening tool for sarcopenia and prognostic indicator for patients with esophageal cancer.","volume":"22","author":"Zheng","year":"2022","journal-title":"BMC Geriatr"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1007\/s10147-024-02539-7","article-title":"Impact of the serum creatinine and cystatin C ratio for prediction of sarcopenia and prognosis in biliary tract cancer.","volume":"29","author":"Fukushima","year":"2024","journal-title":"Int J Clin Oncol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1233768","DOI":"10.3389\/fonc.2024.1233768","article-title":"The coexistence of myosteatosis and the creatinine\/cystatin C ratio are determinants of outcomes in cholangiocarcinoma patients undergoing curative surgery.","volume":"14","author":"Liu","year":"2024","journal-title":"Front Oncol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"2913","DOI":"10.1245\/s10434-024-14969-8","article-title":"Prognostic value of myosteatosis and creatinine-to-cystatin c ratio in patients with pancreatic cancer who underwent radical surgery.","volume":"31","author":"Bi","year":"2024","journal-title":"Ann Surg Oncol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1111\/hepr.13230","article-title":"Ratio between estimated glomerular filtration rates of creatinine and cystatin C predicts overall survival in patients with hepatocellular carcinoma.","volume":"49","author":"Tamai","year":"2019","journal-title":"Hepatol Res."},{"key":"B31","doi-asserted-by":"publisher","first-page":"5017","DOI":"10.21037\/apm-20-2366","article-title":"Creatinine-to-cystatin C ratio as a marker of skeletal muscle mass for predicting postoperative complications in patients undergoing gastric cancer.","volume":"10","author":"Gao","year":"2021","journal-title":"Ann Palliat Med."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1111\/ggi.70206","article-title":"Association of serum creatinine-cystatin C ratio with hospital-associated complications and post-discharge mortality.","volume":"25","author":"Yamada","year":"2025","journal-title":"Geriatr Gerontol Int"}],"container-title":["Frontiers in Nutrition"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnut.2026.1834663\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T04:24:53Z","timestamp":1784867093000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnut.2026.1834663\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,24]]},"references-count":32,"alternative-id":["10.3389\/fnut.2026.1834663"],"URL":"https:\/\/doi.org\/10.3389\/fnut.2026.1834663","relation":{},"ISSN":["2296-861X"],"issn-type":[{"value":"2296-861X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,24]]},"article-number":"1834663"}}